1. Aarkstore.com announces, The Latest market research report is available in
its vast collection:
Genital Warts (Condylomata Acuminata) – Pipeline Review,
H1 2012
You can also request for sample page of above mention reports on
sample@aarkstore.com
Summary
Global Markets Direct’s, Genital Warts (Condylomata Acuminata) - Pipeline Review,
H1 2012, provides an overview of the Genital Warts (Condylomata Acuminata)
therapeutic pipeline. This report provides information on the therapeutic
development for Genital Warts (Condylomata Acuminata), complete with latest
updates, and special features on late-stage and discontinued projects. It also reviews
key players involved in the therapeutic development for Genital Warts
(Condylomata Acuminata). Genital Warts (Condylomata Acuminata) - Pipeline
Review, H1 2012 is built using data and information sourced from Global Markets
Direct’s proprietary databases, Company/University websites, SEC filings, investor
presentations and featured press releases from company/university sites and
industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the
availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Genital Warts (Condylomata
Acuminata).
- A review of the Genital Warts (Condylomata Acuminata) products under
development by companies and universities/research institutes based on
2. information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from
discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined
therapeutics.
Table of contents:
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Genital Warts (Condylomata Acuminata) Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Genital Warts (Condylomata Acuminata) 7
Genital Warts (Condylomata Acuminata) Therapeutics under Development by
Companies 9
Late Stage Products 10
Comparative Analysis 10
Mid Clinical Stage Products 11
Comparative Analysis 11
Discovery and Pre-Clinical Stage Products 12
Comparative Analysis 12
Genital Warts (Condylomata Acuminata) Therapeutics – Products under
Development by Companies 13
Companies Involved in Genital Warts (Condylomata Acuminata) Therapeutics
Development 14
Helix BioPharma Corp. 14
Inovio Biomedical Corporation 15
Merck & Co., Inc. 16
MediGene AG 17
Anaconda Pharma 18
Telormedix SA 19
Genetic Immunity, LLC 20
Moberg Derma AB 21
3. Genital Warts (Condylomata Acuminata) – Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
Interferon Alpha-2b - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Polyphenon E Ointment - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
TMX-202 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
V503 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
HupaDerm Vaccine - Drug Profile 33
Product Description 33
Mechanism
List of Figures
List of Tables are also include.
For more related Reports Plz follow The link:
Pipeline Review, H1 2012
